STAAR Surgical Company (STAA) 45th Annual William Blair Growth Stock Conference summary

Company overview and market position

• Operates as a global leader in ophthalmic surgery with a 43-year history and proven, reversible lens technology that preserves the cornea and offers UV protection.

• Holds the number one refractive share in Japan and about 12% global market share, with significant presence in 75 countries.

• Faces slower U.S. growth but expects improvement as surgeon and patient confidence increases.

• Competes primarily with LASIK, emphasizing advantages like no tissue removal, rapid recovery, and suitability for high diopter cases.

• Collamer lens material is a key differentiator, offering biocompatibility and long-term stability.

Financial performance and operational updates

• 2024 revenue reached $313.9 million, down 3% year-over-year due to China market headwinds.

• Gross margins dropped from 78.9% to 65.8% amid lower production and China sales decline; restructuring led to $22.7 million in charges.

• SG&A is being reduced to a $225 million run rate, with most employee terminations completed.

• Ex-China business grew 9% year-over-year despite global macroeconomic challenges.

• Switzerland manufacturing ramp-up is expected to mitigate tariff risks and improve long-term margins.

Strategic priorities and growth opportunities

• Focused on expanding beyond the current 5.2 million annual procedures to reach the broader population using glasses or contacts.

• Regulatory wins in China, Taiwan, and Brazil support future growth, with new product launches like EVO+ or V5 in China planned for Q4.

• China remains a critical and growing market despite recent inventory and tariff issues, which are expected to be temporary.

• India is seen as a future growth market as economic conditions improve; U.S. growth hinges on building surgeon and patient confidence.

• Myopia prevalence is rising globally, expected to reach 50% by 2050, expanding the addressable market.